Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
PaperCitations, authors & open-access status
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 672 citations, 2021 year and hybrid oa status.
672
Citations
2021
Year
hybrid
OA Status